Comparative Pharmacology
Head-to-head clinical analysis: ACIPHEX versus PANTOPRAZOLE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACIPHEX versus PANTOPRAZOLE SODIUM.
ACIPHEX vs PANTOPRAZOLE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
20 mg orally once daily; duration: 4-8 weeks for erosive esophagitis, 4 weeks for GERD, 24 weeks for H. pylori eradication (triple therapy: AcipHex 20 mg + amoxicillin 1000 mg + clarithromycin 500 mg twice daily for 7 days), 4 weeks for duodenal ulcer, up to 12 months for pathological hypersecretory conditions.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
None Documented
None Documented
Plasma half-life 1-2 hours, but pharmacodynamic half-life (acid suppression) >24 hours due to accumulation in parietal cell canaliculi.
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Hepatic metabolism, primarily via CYP2C19 and CYP3A4; ~90% eliminated as metabolites in urine, <1% unchanged; remainder in feces.
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor